Letters to the Editor
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.
Dual Myeloid Disorder Treated with Two Drug Association
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: January 6, 2025
Accepted: February 13, 2025
Accepted: February 13, 2025
996
Views
892
Downloads
82
HTML
Authors
The concomitant presence of BCR-Abl1 and JAK2/CALR mutations in Myeloproliferative neoplasms (MPNs) is rare. The clinical presentation of Chronic Myelogenous Leukemia (CML) and Ph-negative MPN may vary, but CML seems to play a dominant role, so patients usually receive treatment with tyrosine kinase inhibitor (TKI) only. The second Ph-negative MPN becomes evident under the selective pressure of the TK.I.
Downloads
Download data is not yet available.
Citations
Khoury J.D., Solary E., Abla O. et al. (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia; 36(7):1703-1719.
Zanelli M., Bisagni A., Sanguedolce F. et al.(2023) Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination. Front oncol.; 13: 01-14.
Soderquist CR, Ewalt MD, Czuchlewski DR, et al. (2018) Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology 31(5):690–704.
Martin-Cabrera P, Haferlach C, Kern W, et al. (2014) BCR-ABL1-positive and JAK2 V617F-positive clone in 23 patients with both aberrations reveal biologic and clinical importance. BJH (2017) 176:131–43.
Iurdo A., Gianelli U., Rapezzi D et al. (2014) Imatinib and Roxilitinib association: first experience in two patients. Haematologica: 99: e76-77
Zhou A, Knoche EM, Engle EK, Fisher DAC and Oh ST (2015) Concomitant JAK2V617F positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 5:e351.
Pieri L, Spolverini A, Scappini B, et al. (2011) Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood 118(12):3445–6.
Verstovsek S, Mesa RA, Gotlib J, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med.; 366: 799-807.
Bader G. and Dreiling B. (2019) Concurrent Jak2-Positive Myeloproliferative disorder and Chronic myelogenous leukaemia: a novel entity? A case report with review of the literature. Journal of Investigative medicine:vol 7: 1-5.
Kandarpa M, Wu YM, Robinson D et al. (2017) Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. AJH 92:555–61.
Boddu P, Chihara D, Masarova L. , Pemmaraju N., Patel KP and Verstovsek S. (2018) The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol;97 (11):2071-2080.
Zhao Y, Reddi D, McCracken J, et al. (2022) Sequential development of JAK2V617F mutation and BCR-ABL1 fusion in individual patients with myeloproliferative neoplasms. A linear clonal evolution or parallel clonal competition? Arch Pathol Lab Med 146:710–7.
Zhang Y, Bi H, Wang Y, Chen L, et al. (2022) BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. Blood Sci 4:199–204.
Sorà F, Chiusolo P, Autore F, et al. (2021) Is allogenic transplantation an option in patients affected by concurrent myelofibrosis and chronic myeloid leukemia (CML)? Mediterr J Hematol Infect Dis 13(1): e2021062.
Ryu J, Chu D, Park B, et al. (2022) Rare case of accelerated-phase chronic myeloid leukemia diagnosed during treatment for JAK2 V617F-positive primary myelofibrosis. Lab Med 53:e140–4.
How to Cite
“THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated with Two Drug Association” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025023. doi:10.4084/MJHID.2025.023.
Copyright (c) 2025 Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
